News

Demonstrating innovations in respiratory and allergy diagnostics with the NObreath® and Gastrolyzer® range. Bedfont® Scientific Ltd., an innovative leader in the medical breath analysis industry with almost 50 years of experience, is pleased to join thousands of healthcare experts at...

Bedfont® celebrates global expansion by delivering UK healthcare solutions to a growing global audience. Bedfont® Scientific Limited, an innovative MedTech company that specialises in designing and manufacturing medical breath analysis devices, is thrilled to have been shortlisted in the Export...

Included with every Gastrolyzer® range order, Bedfont® Scientific Limited provides practical resources designed to support and simplify hydrogen and methane breath testing (HMBT). One such resource was the interpretation wheel, which, until December 2025, offered clinicians a quick reference for...

Bedfont® Scientific Limited to showcase why the NObreath® is the FeNO device of choice at this year’s global event. World leaders in breath analysis Bedfont® Scientific Ltd. are pleased to be attending this years American Thoracic Society (ATS) International Conference,...

In 2019, 262 million people worldwide had asthma, with 455,000 deaths from the chronic condition1, stark figures that highlight asthma control still needs improvement. Most people living with asthma believe that no physical symptoms mean their asthma is controlled, but...

Over 28 million people in the United States (US) have asthma1,2, with the condition named as the leading chronic disease in children, affecting approximately 4.9 million under the age of 182,3. In the US, asthma is one of the most...